Background Bisphenol F (BPF) and bisphenol S (BPS) are increasingly used in consumer products as substitutes for bisphenol A (BPA), a widespread environmental endocrine disruptor and putative obesogen. However, studies on the effects of BPF and BPS on obesity in human beings are scarce. We examined the associations of BPA, BPF, and BPS exposure with obesity in US adults.
Introduction
Obesity is a worldwide epidemic with critical and multiple comorbidities. 1 The rapid increase of obesity cannot solely be attributed to genetic background and changes in diet, exercise, and ageing. Accumulating evidence suggests that environmental chemicals, particularly endocrine-disrupting chemicals, might also have a role in the increase of obesity. 2, 3 Bisphenol A (BPA) is a synthetic chemical that has been widely used in consumer products, such as food packaging, dental sealants, and thermal receipts. 4 BPA exposure from food and water consumption, dust inhalation, or skin contact is ubiquitous in human beings. 5 National biomonitoring surveys 6 showed that BPA was present in urine samples of 95% of US adults in 2005. As an endocrine-disrupting chemical, BPA has received immense attention because of its toxicological hazard and potential adverse health effects. Evidence from animal studies and human epidemiologic studies suggests that BPA might be a putative environmental obesogen. 7 BPA can promote adipocyte differentiation and proliferation, and induce adipocyte hypertrophy. 2 In the past two decades, there has been a rapid increase of BPA-free products on the market because of concerns about the health effects of BPA. Subsequently, BPA substitutes, such as bisphenol F (BPF) and bisphenol S (BPS), are being used in some BPA-free products instead. 8, 9 For example, BPS was found in all thermal receipt paper samples and 87% of bill samples from four countries, the USA, Japan, Korea, and Vietnam. 9 BPF has been detected in high concentrations in vegetables and seafood in China. 10 From 2000 to 2014, measured levels of BPF and BPS exposure in human beings increased, although their levels are lower than that of BPA. 11 The detection frequency of BPF was 88% and for BPS was 74% in 2014 in US adults. 11 However, the safety of BPF and BPS is unclear, which is of concern because these agents are structural analogues to BPA. Although a growing number of in-vitro studies and invivo studies suggest that BPF and BPS might have endocrine-disrupting effects similar to BPA, human studies on the health effects of BPF and BPS exposures are scarce. 12 Therefore, we examined the associations of BPA, BPF, and BPS with obesity in a nationwide population-based study.
Methods

Study design and participants
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional, nationally representative survey of the US population not living in institutions, administered by the National Center for Health Statistics at the US Centers for Disease Control and Prevention. 13 The NHANES collects data on demographics, socioeconomic status, diet, lifestyle, and medical conditions, and specimens for laboratory tests. Data from the NHANES are publicly released in 2-year cycles.
For this analysis, we used data from NHANES 2013-14, when urinary concentrations of BPF and BPS were first measured. 10 175 participants, including children and adults, were included in NHANES 2013-14 through a multistage probability sampling design to represent the civilian non-institutionalised resident population of the USA. All participants aged 6 years and older from a randomly selected, one-third sample were eligible for measure ments of urinary concentrations of BPA, BPF, and BPS. The analytical population in the present study consisted of adults aged 20 years and older who had available data on measurements of BPA, BPF, and BPS. We excluded pregnant women and individuals with cancer from analyses because pregnancy and cancer can affect bodyweight and alter the disposition of xenobiotics. The NHANES has been approved by the National Center for Health Statistics Ethics Review Board. Written informed consent was obtained from all participants.
Procedures
Urinary concentrations of BPA, BPF, and BPS were measured using on-line solid phase extraction coupled to high performance liquid chromatography and tandem mass spectrometry. 13 The lower limits of detection (LLOD) were 0·2 µg/L for BPA, 0·2 µg/L for BPF, and 0·1 µg/L for BPS. For concentrations below the LLOD (5% of BPA measurements, 35% of BPF measurements, and 9% of BPS measure ments), NHANES staff assigned a value of the LLOD divided by the square root of two. To account for urine dilution, concentrations of all three target analytes were adjusted for urinary creatinine concentrations in all the analysis models in this study, as previously recommended. 14 Trained health technicians assessed weight, height, and waist circumference according to the NHANES Anthropometry Procedures Manual. 13 General obesity was classified as body-mass index (BMI) of 30 kg/m2 or higher, and abdominal obesity was defined as waist circum ference of 102 cm or higher in men and 88 cm or higher in women. Information on age, sex, race or ethnicity, family income, education, and smoking status was collected using questionnaires. Race or ethnicity was categorised into Hispanic (including Mexican and non-Mexican Hispanic), non-Hispanic white, non-Hispanic black, and other race or ethnicity. Family income-to-poverty ratio
Research in context
Evidence before this study We searched PubMed for research articles and reviews published in English from database inception to Dec 20, 2016 . We used the search terms "bisphenol A", "bisphenol F", "bisphenol S", "BPA substitute", "BPA alternative", "obesity", "adiposity", "obesogen", and "weight". Findings on the association between bisphenol A (BPA) and obesity have been inconsistent, and a published systematic review highlighted the need for further investigation. In certain populations, BPA exposure is reducing while exposure of BPA substitutes, such as bisphenol F (BPF) and bisphenol S (BPS), is increasing. In-vitro studies and in-vivo studies have shown that BPF and BPS have endocrine-disrupting effects similar to BPA. However, human studies on effects of BPF and BPS exposures on obesity are scarce.
Added value of this study
To our knowledge, this is the first human study to examine the associations of BPF and BPS with obesity. This study was based on data from the National Health and Nutrition Examination Survey, a nationwide population-based study among US population. We found that, after adjustment for other risk factors for obesity, urinary BPA concentration was significantly associated with a higher risk of both general obesity and abdominal obesity. Current urinary concentrations of BPF and BPS were not significantly associated with obesity.
Implications of all the available evidence
This study has important clinical and public health implications. At the current exposure level, BPF and BPS exposure does not seem to contribute significantly to obesity epidemic in US adults. However, whether BPF and BPS pose an increased risk of obesity at the same population exposure levels as BPA remains unknown. With a rising exposure of BPF and BPS as substitutes of BPA, continued biomonitoring of these chemicals in populations and further investigations on their health effects are needed.
was categorised as 1·30 or lower, 1·31-3·50, and greater than 3·50. 15 Self-reported education status was grouped as lower than high school, high school, and college or higher. Individuals who smoked less than 100 cigarettes in their lifetime were defined as never smokers; those who had smoked more than 100 cigarettes, but did not smoke at the time of survey, were considered former smokers; and those who had smoked 100 cigarettes in their lifetime and smoked cigarettes at the time of survey were current smokers, in accordance with the National Center for Health Statistics classifications. 13 Participants were asked questions about physical activity, from which metabolic equivalent of task min per week were derived according to the Global Physical Activity Questionnaire Analysis Guide. 16 Dietary information was collected by 24-h dietary recall interview and total energy intake was calculated using the US Department of Agriculture Automated Multiple-Pass Method.
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Statistical analysis
The NHANES used a complex, multistage probability sampling design to represent a national, civilian, noninstitutionalised, US population. Therefore, weighted estimates were applied to account for the differential probability of selection, non-response adjustment, and adjustment to independent population controls. The Taylor series linearisation method was used for variance estimation to account for stratification and clustering, following the NHANES Analytic Guidelines. 13 We used χ² tests to analyse categorical variables and analysis of variance to analyse continuous variables. We log-transformed concentrations of BPA, BPF, and BPS before analysis because their distributions were skewed. We used Pearson correlations with sample weights to compute correlation coefficients among log-transformed BPA, BPF, and BPS concentrations. We used logistic regression to estimate the odds ratios (ORs) of general or abdominal obesity according to quartiles of urinary BPA, BPF, and BPS concentrations. We used linear regression to estimate the association of urinary concentrations of BPA, BPF, and BPS with BMI and waist circumference. We adjusted for age, sex, and urinary creatinine in model 1. Additionally, race or ethnicity, education, family income-to-poverty ratios, smoking status, physical activity, and total energy intake were included in model 2. We included BPA, BPF, and BPS concentrations in the same model (model 3) to mutually adjust for each other. Categorical covariates included a subcategory for missing data, if necessary. To test linear associations across categories of BPA, BPF, or BPS concentrations, we assigned the median values of log-transformed BPA, BPF, or BPS concentrations for each category and fitted the median values as continuous variables in the models.
We evaluated effect modification by sex (men, women) and race or ethnicity (white, non-white) by doing stratified analyses. We derived p values for heterogeneity from the multiplicative interaction term coefficient (exposure variable × effect modifier variable) added to the main effects multivariable model.
To assess the robustness of our findings, we did sensitivity analyses by excluding individuals with diabetes, cardiovascular disease, and chronic obstructive pulmonary disease (COPD) because these conditions might have affected bodyweight. Individuals who were underweight (BMI <18·5) were excluded in another sensitivity analysis, given that underweight might have resulted from unknown reasons irrelevant to the exposure of interest.
All statistical analyses were done in SAS software (version 9.4). p<0·05 was considered statistically significant.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
1709 adults aged 20 years and older were randomly selected for measurements of BPA, BPF, and BPS, of whom 24 were pregnant women and 164 had cancer and were excluded from analyses. 1521 participants were included in the analysis, of whom 732 (48%) were men. Median urinary concentrations were 1·3 ng/mL (IQR 0·6-2·5) for BPA, 0·3 ng/mL (0·1-1·1) for BPF, and 0·4 ng/mL (0·1-0·9) for BPS. Younger individuals, men, and nonHispanic blacks were more likely to have high levels of BPA (table 1) . Non-Hispanic blacks and individuals with lower family income and levels of education were more likely to have elevated levels of BPS than those with higher family income or education levels (table 1) . No significant differences of population characteristics were found for BPF (table 1) . Urinary concentrations of the three bisphenols were significantly correlated with each other; the Pearson correlation coefficients were 0·27 between BPA and BPF (p<0·0001), 0·33 between BPA and BPS (p<0·0001), and 0·20 between BPF and BPS (p<0·0001).
The weighted prevalence of general obesity was 39% (SE 1·8%) and 58% (1·4%) for abdominal obesity. Higher concentrations of BPA, BPF, and BPS were observed in adults with general obesity than adults who were not obese; median urinary concentration was 1·5 ng/mL (IQR 0·7-2·8) for BPA, 0·4 ng/mL (0·1-1·3) for BPF, and 0·4 ng/mL (0·2-1·0) for BPS in individuals with general obesity, and 1·1 ng/mL (0·5-2·3) for BPA, 0·3 ng/mL (0·1-0·9) for BPF, and 0·3 ng/mL (0·1-0·8) for BPS in individuals with non-general obesity (appendix).
In multivariable analyses, urinary BPA concentrations, but not concentrations of BPF or BPS, were significantly associated with obesity (tables 2, 3). After adjustment for demographic factors, socioeconomic factors, lifestyle Table 1 continues on next page) factors, and urinary creatinine concentrations, the OR for general obesity comparing the highest with lowest quartile of each bisphenol was 1·78 (95% CI 1·10-2·89; p=0·04 for trend) for BPA, 1·02 (0·70-1·47; p=0·81 for trend) for BPF, and 1·22 (0·81-1·83; p=0·30 for trend) for BPS. The corresponding OR for abdominal obesity was 1·55 (95% CI 1·04-2·32; p=0·02 for trend) for BPA, 1·05 (0·68-1·63; p=0·99 for trend) for BPF, and 1·16 (0·72-1·88; p=0·54 for trend) for BPS. As expected, we observed similar findings in analyses on the associations of urinary concentrations of these bisphenol compounds with continuous BMI and waist circum ference (tables 4, 5).
There was no significant interaction between sex and bisphenol concentration or race or ethnicity and bisphenol concentration in relation to obesity, although the associations between BPA concentration and obesity seemed stronger in men than women and stronger in white people than non-white people. The OR for general obesity comparing the highest with the lowest quartile of urinary BPA concentration was 2·10 (95% CI 1·20-3·68; p=0·03 for trend) in men and 1·46 (0·76-2·80; p=0·18 for trend) in women (appendix). The OR for general obesity for BPA was 2·41 (1·32-4·43; p=0·01 for trend) in white people and 1·18 (0·77-1·82; p=0·55 for trend) in non-white people (appendix). The associations of BPF and BPS with general obesity did not differ by sex or race or ethnicity, and similar results were observed for abdominal obesity (appendix).
The associations of BPA, BPF, and BPS concentrations with general and abdominal obesity did not change appreciably in sensitivity analyses when excluding participants with cardiovascular disease, diabetes, and COPD, or excluding individuals who were underweight (appendix).
Discussion
To our knowledge, this is the first study to examine the associations of BPF and BPS concentrations with obesity in human beings. We found that urinary concentrations of BPF and BPS at current exposure levels were not significantly associated with obesity, although there were significant associations of BPA exposure with general and abdominal obesity. These results indicate that current levels of environmental exposure to BPF and BPS do not seem to contribute significantly to the obesity epidemic in US adults. However, two important facts should be taken into account in the interpretation of the absence of significant associations of BPF and BPS with obesity in this population. First, the median urinary concentrations of BPF (0·3 ng/mL) and BPS (0·4 ng/mL) at the survey time were lower than that of BPA (1·3 ng/mL) in our population. Whether BPF and BPS pose an increased risk of obesity at the same population exposure levels as BPA remains unknown. Second, BPF and BPS have only replaced BPA in some products in the past two decades, whereas obesity could be a progressive condition as a result of chronic exposure to an obesogenic environment over many years. It is worth noting that we observed a marginally significant association between the third quartile of BPS and BMI. A possible explanation for this might be that BPS plays a part in promoting weight gain, but people who are affected have not yet developed clinically significant obesity.
Evidence from laboratory studies suggests that BPF and BPS have obesity-promoting effects. 12, [17] [18] [19] [20] [21] [22] [23] [24] Biologically, BPF and BPS are thought to be potential endocrine disruptors because they have similar chemical structures to BPA. 12, 17 Findings from in-vivo studies and in-vitro studies have shown that BPF and BPS have some BPAlike oestrogenic activities, such as binding to nuclear oestrogen receptors and altering adiponectin production. 12, 18 They also have effects on peroxisome proliferator-activated receptor (PPAR) γ signalling pathway, a main target of obesogens, to increase lipid accumulation and differentiation of preadipocytes into adipocytes. [19] [20] [21] Additionally, BPF could affect adiponectin production and secretion. 18 Moreover, results from a 2016 study 22 showed that BPS exposure led to differential expression of genes related to adipogenesis and lipid metabolism, and it had effects on adipose-specific transcriptional changes earlier than BPA. BPF and BPS might even have some additional disruptive effects that are different to BPA and need to be explored in the future. 12 Findings from an in-vitro study 23 showed that 
Data are OR (95% CI), unless otherwise specified. Model 1: adjusted for age (years), sex (men, women), and urinary creatinine (quartiles). Model 2: model 1 + race or ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, and other race), education (lower than high school, high school, college or higher), family income (family income to poverty ratio: ≤1·30, 1·31-3·50, >3·50, or missing), cigarette smoking (never, past, current), physical activity (<600, 600-1199, ≥1200 MET min per week), and total energy intake (quartiles). Model 3: model 2 + mutual adjustment for BPA, BPF, and BPS. BPA=bisphenol A. BPF=bisphenol F. BPS=bisphenol S. NHANES=National Health and Nutrition Examination Survey. OR=odds ratio. ref=reference. MET=metabolic equivalent. 
Data are OR (95% CI), unless otherwise specified. Model 1: adjusted for age (years), sex (men, women), and urinary creatinine (quartiles). Model 2: model 1 + race or ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, and other race), education (lower than high school, high school, college or higher), family income (family income to poverty ratio: ≤1·30, 1·31-3·50, >3·50, or missing), cigarette smoking (never, past, current), physical activity (<600, 600-1199, ≥1200 MET min per week), and total energy intake (quartiles). Model 3: model 2 + mutual adjustment for BPA, BPF, and BPS. BPA=bisphenol A. BPF=bisphenol F. BPS=bisphenol S. NHANES=National Health and Nutrition Examination Survey. OR=odds ratio. ref=reference. MET=metabolic equivalent. both BPA and BPS can enhance 3T3-L1 adipocyte differentiation in a dose-dependent manner, and through direct comparison, BPS is a more potent obesogen than BPA. In another in-vitro study, 24 similar potency to induce obesity was found for BPA and BPS, but they might induce obesity through two different metabolic pathways. Clearly, whether BPF and BPS are safe substitutes to BPA in terms of obesity risk in human beings needs further investigation. One cannot exclude the notion that BPF and BPS exposure at similar levels to BPA could have similar obesogenic effects.
The observed significant associations of urinary BPA concentration with general obesity and abdominal obesity in this study are consistent with several earlier studies. 25 Several pathways might be involved in the mechanisms of weight gain induced by BPA and its derivatives. 3 Known as a xenoestrogen, BPA can bind to oestrogen receptors to change the release of adiponectin, which play a part in glucose regulation and energy balance. 26 BPA can also activate PPAR γ, 27 and alter metabolic processes through epigenetic mechanisms, such as DNA methylation and histone modification. 
Model 1: adjusted for age (years), sex (men, women), and urinary creatinine (quartiles). Model 2: model 1 + race or ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, and other race), education (lower than high school, high school, college or higher), family income (family income to poverty ratio: ≤1·30, 1·31-3·50, >3·50, or missing), cigarette smoking (never, past, current), physical activity (<600, 600-1199, ≥1200 MET min per week), and total energy intake (quartiles). 
Model 1: adjusted for age (years), sex (men, women), and urinary creatinine (quartiles). Model 2: model 1 + race or ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, and other race), education (lower than high school, high school, college or higher), family income (family income to poverty ratio: ≤1·30, 1·31-3·50, >3·50, or missing), cigarette smoking (never, past, current), physical activity (<600, 600-1199, ≥1200 MET min per week), and total energy intake (quartiles). Additionally, BPA, a selective oestrogen receptor modulator, acts as an oestrogen agonist or antagonist in a tissue-specific way, which makes the exposure to BPA even more complex. 30 Moreover, BPA's predominant metabolite, BPA-glucuronide, which was previously believed to be inactive, can actually induce preadipocyte differentiation and fat accumulation as well. 31 In this study, we observed a stronger association between BPA and obesity in men than women, which could be explained by lower urinary BPA concentrations in women. We also observed a stronger association in white people than non-white people, although white people have lower urinary BPA concentrations. Such racial or ethnic differences in the association have also been reported in other studies, 32 but the underlying mechanisms remain to be understood.
This study has important clinical and public health implications. BPF and BPS have already been used, on a large scale, as substitutes of BPA in manufacturing of plastics and epoxy resins. The broad applications of BPF and BPS result in the ubiquitous presence in our daily life, including in food, food packaging, personal-care products, paper products, drinking water, and indoor dust. 12, 33 In parallel with a gradual decrease in BPA concentrations in the US population, there has been increasing BPF and BPS concentrations reported in the past two decades. 11 With rising exposure to BPF and BPS from common consumer products, a thorough investigation on health effects of BPF and BPS in human beings is needed.
This study has several strengths. It was based on nationally representative data from the population-based NHANES study, which can allow good generalisability of our findings to a broader population. Additionally, the rich data from the NHANES, including comprehensive information about demographic, socioeconomic, and lifestyle factors, provide the opportunity to control for confounding from a variety of obesity-related risk factors.
We acknowledge that there are some limitations in our study. First, our data were from a cross-sectional survey, which is incapable of establishing a temporal relation or drawing causal inference from the observed associations. However, most findings from the NHANES on health effects of BPA have been confirmed in subsequent cohort studies and meta-analyses. 25 Second, spot urine samples were collected to measure concentrations of BPA and its substitutes due to the perceived challenges and difficulties in collecting 24-h urine samples. Although within-person and between-person variability in spot urine samples exist, findings from previous studies have shown that urinary concentration of BPA based on one spot urine can adequately reflect the average exposure of a population to BPA when the population is sufficiently large and samples are randomly collected relative to meal ingestion times and bladder emptying times. 34 Third, the proportion of participants with urinary BPF concentrations below the LLOD is relatively high. Although this did not appreciably affect the categorisation of BPF exposure in our categorical data analysis, the association between BPF and obesity warrants confirmation in other populations exposed to higher levels of BPF than that recorded in this study. Fourth, the sources of BPA, BPF, and BPS exposure might not be entirely the same. However, information about sources of the exposures is scarce. Therefore, we could not determine their individual confounding patterns to date. Fifth, although we adjusted for many potential confounders, the possibility of residual confounding by other unknown factors cannot be ruled out. Finally, the sample size in this study is not well powered to detect a weak association (eg, BPF and obesity). Future studies with a larger sample size than used in this study are needed to confirm our findings.
In this population-based, cross-sectional study, there were significant associations of BPA exposure with general and abdominal obesity. Urinary concentrations of BPF or BPS at current population exposure levels were not significantly associated with obesity in US adults. However, whether BPF and BPS at the same population exposure levels as BPA pose an increased risk of obesity is not known. Additionally, BPA has only been substituted with BPF and BPS in the past two decades. Given the gradual decrease in BPA and increase in BPF and BPS exposure in populations, continued biomonitoring of these bisphenols and further investigations on their health effects in human beings are warranted.
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